Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness

• Status: Completed
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13, an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Northwestern University

Criteria

Inclusion Criteria:

For all Individuals

• Male and female subjects

• Ages 18 - 40 years

• General intellectual abilities falling broadly within the average range (estimated IQ between 80 - 119)

• Sufficient ability to understand study requirements and provide written informed consent

For Patients

-Diagnosis of Schizophrenia or Schizoaffective Disorder

Exclusion Criteria:

For all individuals:

• History of neurologic disorder or systemic medical condition that may interfere with central nervous system function

• History of seizures

• History of heard injury with loss of consciousness or concussion

• Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid, or other agent that is being abused in the opinion of the investigator

• Females who are currently pregnant or plan to become pregnant during the study period

• History of allergy, sensitivity, or intolerance to N-methyl-D-Aspartate receptor (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone

• History of any ferromagnetic object in the body

• Presence of any medical device or implant for which MRI is contraindicated including cardiac pacemaker, aneurysm clip, cochlear implant, copper intrauterine device (IUD), neurostimulator, or any other device deemed unsafe

• Bullet or shrapnel in body

• Metallic braces or permanent retainer

• Significant claustrophobia

For Healthy Individuals

• Personal history of any Axis I disorder according to SCID criteria

• History of treatment with antidepressant, antipsychotic, stimulant,sedative/ hypnotic, mood stabilizing, or anticholinergic medications or lithium

• History among first-degree family members of any psychotic illness or major mood disorder (e.g., major depressive disorder, recurrent; bipolar I or II disorder)

For Patients

• Treatment with Clozaril

• Change in medication within 1 month

• Hospitalization within 1 month